{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-men/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"0b85e5c6-7cc0-58a2-8889-5c211efc01d6","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 27d8655d-678d-47b0-81ee-ec24d6ad3999 --><h2>Trimethoprim</h2><!-- end field 27d8655d-678d-47b0-81ee-ec24d6ad3999 -->","summary":"","htmlStringContent":"<!-- begin item b1576788-4ee9-41e3-b7da-5561081c83bb --><!-- end item b1576788-4ee9-41e3-b7da-5561081c83bb -->","topic":{"id":"335f7066-6009-52c3-bb1e-bb68e732e41f","topicId":"933b760e-86fa-4ba1-b937-3c052be97e83","topicName":"Urinary tract infection (lower) - men","slug":"urinary-tract-infection-lower-men","lastRevised":"Last revised in November 2018","chapters":[{"id":"a1f0f874-afae-5abc-bfc0-b8aff4687b8d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"722a30e1-802e-50da-aeb2-55a320f811e0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"54bfd7d0-4d24-5c97-b344-6dc7fe0500bf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d780254d-b3a6-5120-a061-adbfa9d6c3d3","slug":"changes","fullItemName":"Changes"},{"id":"ded6008d-05b8-54a3-9be7-e1f9c635b466","slug":"update","fullItemName":"Update"}]},{"id":"281305b2-29ee-5ee3-879d-2a1c6115b107","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"28ce53d8-a9de-582e-b21f-63a49c9518b7","slug":"goals","fullItemName":"Goals"},{"id":"80a08351-02e8-5bf8-9865-b1f745f759f9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c65e1ea0-2e57-5742-8d13-e19bbdabcf5b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7c3a6d64-9cf2-5b7f-8c66-ac2aa0dab8b9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edc3c38c-1e69-5da3-8da7-174dd323fee3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a235fb13-94fa-5fa1-ac15-eae46288950c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f1cf9c73-1a32-5912-8f20-a511a2baa05c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"423dc347-3ec3-514e-bd33-486d46645934","slug":"definition","fullItemName":"Definition"},{"id":"57c35511-4b16-5330-9634-f12fd1accf63","slug":"causes","fullItemName":"Causes"},{"id":"479b7fa1-3b50-51c3-89ac-1373a3aec46a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c6d01476-282e-5662-8378-40f864eedc0e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc3e67c4-09a3-557a-b9d1-7bd1b9692fd3","slug":"complications","fullItemName":"Complications"}]},{"id":"a4c4a87e-e501-53b8-bdd5-15185f853016","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"61ab2e56-53dc-5875-a0bc-41dc08a4b6b8","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"3f5567ff-0ab4-5228-80d9-6b8addad17e0","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"e65bf3d7-aefc-572c-bf7b-6eb6573d7fb6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"923818be-e371-5af0-91a7-c470d34dac3c","fullItemName":"Management","slug":"management","subChapters":[{"id":"e3d61967-efe7-54fc-acbd-2e51935ca714","slug":"lower-uti-in-men","fullItemName":"Scenario: Lower UTI in men"},{"id":"f0357d1a-f5ca-5139-ac96-98e285b29c36","slug":"recurrent-uti-in-men","fullItemName":"Scenario: Recurrent UTI in men"},{"id":"88bc8e33-1e01-5b50-b9c2-362bd372238f","slug":"uti-in-men-with-an-indwelling-catheter","fullItemName":"Scenario: UTI in men with an indwelling catheter"}]},{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0998f6ff-17aa-58cd-8188-2fe8d30e2a63","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"0b85e5c6-7cc0-58a2-8889-5c211efc01d6","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"675b98e1-e1fa-59e0-89d1-0558968a78ba","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"926ae109-9068-515c-a20f-c9cc8b27eb3b","slug":"pivmecillinam","fullItemName":"Pivmecillinam"}]},{"id":"29b9ddff-7312-54b1-9eae-eefca43a368d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"463fe0f7-80e5-5fcd-9f1c-9c1f76f10f30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a4e1c5ad-c809-5d8c-ae1c-d37b4f97dd8c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ac4b6d54-2a63-5545-ad06-0abbe7f6354e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b0a3ea0-682b-5ab3-ae72-bdc7fd586fce","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f7d5ea54-f1b1-59b5-9856-d52f1d73534a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f847f977-daef-5c70-8aa1-eeaf86d9cce7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"235f01e6-f3e2-5784-a197-3b4a11d45527","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"272e25d8-32fb-530d-ac82-d7a7be1ff22a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6203c15a-cf24-4021-8233-a99800a06ad6 --><h3>Contraindications and cautions</h3><!-- end field 6203c15a-cf24-4021-8233-a99800a06ad6 -->","summary":"","htmlStringContent":"<!-- begin item 8148b1e7-9377-47d4-a00e-a99800a06a58 --><!-- begin field 34f7a2b2-0ec7-4087-95b5-a99800a06ad6 --><ul><li><strong>Do not prescribe trimethoprim in people with:</strong><ul><li>Severe hepatic insufficiency, or severe renal insufficiency.</li><li>Blood dyscrasias.</li></ul></li><li><strong>Prescribe trimethoprim with caution in people:</strong><ul><li>With impaired renal function.</li><li>With hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>With acute porphyria.</li><li>Predisposed to folate deficiency — because of the potential anti-folate effect of trimethoprim, there is a risk of further exacerbating folate deficiency in people who are folate deficient, or who are predisposed to folate deficiency (for example elderly people), or who are taking folate antagonists.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>]</p><!-- end field 34f7a2b2-0ec7-4087-95b5-a99800a06ad6 --><!-- end item 8148b1e7-9377-47d4-a00e-a99800a06a58 -->","subChapters":[]},{"id":"e3558202-b50b-523b-8275-64dc0a9f3959","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field beabe97b-0cd9-41b5-aa97-a99800a07d39 --><h3>Adverse effects</h3><!-- end field beabe97b-0cd9-41b5-aa97-a99800a07d39 -->","summary":"","htmlStringContent":"<!-- begin item 66171556-4471-4b7b-962f-a99800a07ccb --><!-- begin field 85d87a9a-5084-4262-8e1d-a99800a07d39 --><ul><li><strong>Blood disorders</strong> — leukopenia, megaloblastic anaemia, thrombocytopenia, agranulocytosis, methaemoglobinaemia.</li><li><strong>Gastrointestina</strong>l — nausea, diarrhoea, vomiting (common).</li><li><strong>Nervous system</strong> — aseptic meningitis (frequency unknown).</li><li><strong>Skin</strong> — pruritus, and skin rashes (common).<ul><li><strong>Rarely: </strong>Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Hyperkalaemia (particularly in the elderly and in HIV patients)</li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>]</p><!-- end field 85d87a9a-5084-4262-8e1d-a99800a07d39 --><!-- end item 66171556-4471-4b7b-962f-a99800a07ccb -->","subChapters":[]},{"id":"4eb5c026-72fd-5aed-94bc-670a9036eedb","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c4264346-1b43-49a9-8826-a99800a08aee --><h3>Drug interactions</h3><!-- end field c4264346-1b43-49a9-8826-a99800a08aee -->","summary":"","htmlStringContent":"<!-- begin item 70724a80-b4f5-4b6d-8d75-a99800a08ab2 --><!-- begin field 8a71ef17-3162-41eb-9125-a99800a08aee --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and </strong><strong>angiotensin-II receptor antagonists </strong><strong>AIIRAs</strong> — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations. </li><li><strong>Azathioprine and mercaptopurine </strong>—<strong> </strong>increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Monitor renal function closely.</li><li><strong>Coumarins (warfarin) </strong>— the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li><strong>Digoxin</strong> — digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics </strong>— hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate (a folate antagonist) </strong>— there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li><strong>Phenytoin </strong>— phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>]</p><!-- end field 8a71ef17-3162-41eb-9125-a99800a08aee --><!-- end item 70724a80-b4f5-4b6d-8d75-a99800a08ab2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}